Baricitinib Versus Tocilizumab for the Treatment of Moderate to Severe COVID-19.

Reid, Nancy Kierstin; Joyner, Kayla Rena; Lewis-Wolfson, Temeka Dawn

Reid, Nancy Kierstin; Joyner, Kayla Rena; Lewis-Wolfson, Temeka Dawn.

Affiliation

Reid NK; Pharmacy Department, Winchester Medical Center, Winchester, VA, USA.
Joyner KR; Department of Pharmacy Practice, Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA, USA.
Lewis-Wolfson TD; Pharmacy Department, Winchester Medical Center, Winchester, VA, USA.

Ann Pharmacother ; 57(7): 769-775, 2023 Jul.

Article in En | MEDLINE | ID: mdl-36314277

Subject(s)

COVID-19; Humans; COVID-19 Drug Treatment; Prospective Studies; Retrospective Studies; Treatment Outcome

Key words

COVID-19; baricitinib; pneumonia; tocilizumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 4_TD / 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: COVID-19 Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Ann Pharmacother Year: 2023 Document type: Article

Fulltext

XML

PubMed Links

Search on Google